4.7 Article

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Journal

JOURNAL OF INFECTIOUS DISEASES
Volume 228, Issue -, Pages S77-S82

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiad246

Keywords

ACTIV-2; clinical trial; COVID-19; monoclonal antibodies

Ask authors/readers for more resources

The clinical trial is registered with identifier NCT04518410.
Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available